Case Discussion: The Role of Neuromodulatory Analgesics in Chronic Pain Management

Title:

Case Discussion: The Role of Neuromodulatory Analgesics in Chronic Pain Management

Topic: Pain Management
Relevant Terms: Chronic Musculoskeletal Pain, Neuromodulation, Neuromodulatory Analgesics, Neuropathic Pain
Primary Audience: This activity is designed for pain specialists; including anesthesiologists; physiatrists; psychiatrists; neurologists; and other healthcare professionals interested in the management of patients with chronic pain conditions.
Launch Date: 15-May-12
Credits: 0.25 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Optimal Chronic Pain Management: From Pathophysiology to Analgesic Selection

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Incorporate neuromodulatory analgesics into a multimodal chronic pain management regimen to specifically target underlying pain pathogenesis in their patients
  2. Evaluate the current understanding of chronic pain pathophysiology and its implication in selecting optimal treatment in managing their patients with chronic pain

    Faculty

    Lesley M. Arnold, MD
    Professor of Psychiatry and Behavioral Neuroscience
    Director, Women's Health Research Program
    University of Cincinnati College of Medicine
    Cincinnati, Ohio
    Daniel J. Clauw, MD
    Professor of Anesthesiology and Medicine (Rheumatology)
    Director, Chronic Pain and Fatigue Research Center
    University of Michigan
    Ann Arbor, Michigan
    Estimated time to complete this activity: 15 minutes

    Program Overview
    Chronic pain is widespread and often poorly managed. A recent American Pain Society (APS) survey estimates that as many as 76 million Americans suffer from moderate-to-severe chronic pain. Despite a wide variety of available pharmaceuticals, chronic pain remains a poorly controlled condition. Patients are often dissatisfied with their current treatment, leading them to change doctors frequently. The major barriers in effective chronic pain treatment include a lack of education and translation of pain pathophysiology into daily clinical practice and underuse of neuromodulatory analgesics to specifically target central dysregulation. These are areas with extensive ongoing studies and rapid emergence of new data that are making it difficult for clinicians to stay abreast of the latest developments. In this activity, the expert faculty will highlight recent studies that provide insights to better understanding the pathophysiology of chronic pain. Furthermore, the faculty will explain the implications of such developments and demonstrate how to translate knowledge regarding chronic pain pathophysiology and neuroplasticity into clinical practice. Using a clinical case simulation, the faculty will discuss the benefit/risk profiles of neuromodulatory analgesics and illustrate how to incorporate neuromodulatory analgesics as part of a multimodal pharmacological regimen for chronic pain management to specifically address underlying pain pathogenesis.

    Physician Accreditation
    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education and is  jointly sponsored by the Postgraduate Institute for Medicine and ACCELMED. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Fee Information
    There is no fee for this educational activity.

    A statement of credit will be issued immediately upon successful completion of the post-test with a score of 70% or better.

    Disclosure of Conflicts of Interest
    The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Dr. Arnold
    Consultant Fees: Daiichi Sankyo, Inc.; Forest Laboratories, Inc.; Grünenthal GmbH; Pfizer Inc. Contracted Research: Forest Laboratories, Inc.; Lilly USA, LLC; Novartis AG; Pfizer Inc.; Takeda Pharmaceutical U.S.A., Inc.

    Dr. Clauw
    Consultant Fees: Forest Laboratories, Inc; Jazz Pharmaceuticals, Inc.; Johnson & Johnson; Lilly USA, LLC; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc. Contracted Research: Forest Laboratories, Inc; Pfizer, Inc.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content: Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP; and Patricia Staples; MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

    The following ACCELMED planners and managers, Jason Xu, PhD, and Jason LeDune hereby state that they or their spouse/life partner have no relationships with commercial interests, and the spouse of Janardhan Sampath, PhD, is an employee of Bristol-Myers Squibb Company.

    Method of Participation and Request for Credit
    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content: Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP; and Patricia Staples; MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

    The following ACCELMED planners and managers, Jason Xu, PhD, and Jason LeDune hereby state that they or their spouse/life partner have no relationships with commercial interests, and the spouse of Janardhan Sampath, PhD, is an employee of Bristol-Myers Squibb Company.

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period May 15, 2012 through May 15, 2013 participants must read the learning objectives and faculty disclosures and study the educational activity.

    PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation following the activity. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

    Media
    Internet

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, ACCELMED, and Lilly USA, LLC do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ACCELMED, and Lilly USA, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    PIM website:  www.pimed.com